Aller au contenu principal
Accès ouvert déclaré 2026 article

Developmental brain programs and biomarker activation in Alzheimer's disease

0Citations signalées — pas une note de qualité
8Institutions déclarées
3Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Recent studies show that serum glial fibrillary acidic protein (GFAP) is highest in healthy infancy and early childhood and then declines steadily with age, while plasma tau protein phosphorylated at position 217 is strikingly elevated in healthy newborns and can exceed values observed in Alzheimer’s disease. Additional evidence indicates that soluble phosphorylated tau forms are not specific to Alzheimer’s disease, as increased tau protein phosphorylated-217 has been reported in MAPT R406W carriers without amyloid pathology and in Niemann-Pick disease type C, where plasma tau protein phosphorylated-217 is associated with disease progression and lysosomal enlargement. These observations invite a broader review of biomarker biology across development, physiological remodeling, and neurodegeneration. We hypothesize that, at least in part, increases of GFAP, tau protein phosphorylated-217 and related biomarkers in Alzheimer’s disease reflect a chronic attempt of the aging brain to reactivate multicellular programs that are physiologically engaged during development, repair, and circuit refinement. In this framework, biomarker elevation does not necessarily indicate that the reactive program is intrinsically toxic. Rather, persistent elevation may index the duration and intensity of unresolved metabolic, inflammatory, vascular, proteostatic, mitochondrial or infectious stressors that keep repair and homeostatic systems engaged until their compensatory capacity is exceeded. Protein precipitation is therefore positioned as a downstream consequence of persistent stress, chronic compensatory activation, increased protein turnover, secretion or processing, and impaired clearance or proteostasis. This Review summarizes the developmental biomarker evidence, examines alternative interpretations, and discusses therapeutic implications focused on upstream stressors and failed resolution rather than biomarker lowering alone.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Developmental brain programs and biomarker activation in Alzheimer's disease
Date Crossref
03/09/2026
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchStress Responses and Cortisol

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.